- Home
- GDOT vs KURA Comparison
GDOT vs KURA Comparison
Compare GDOT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDOT | KURA |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.4M | 841.6M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GDOT | KURA |
|---|---|---|
| Price | $13.39 | $10.89 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $11.00 | ★ $25.56 |
| AVG Volume (30 Days) | 544.8K | ★ 1.8M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $2,080,491,000.00 | $67,482,000.00 |
| Revenue This Year | $11.07 | $28.28 |
| Revenue Next Year | $5.69 | $106.37 |
| P/E Ratio | $40.45 | ★ N/A |
| Revenue Growth | 20.69 | ★ 25.24 |
| 52 Week Low | $9.31 | $5.45 |
| 52 Week High | $15.41 | $12.49 |
Technical Indicators
Market Signals| Indicator | GDOT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 66.74 |
| Support Level | $12.75 | $8.72 |
| Resistance Level | $13.73 | $11.29 |
| Average True Range (ATR) | 0.25 | 0.48 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 63.64 | 95.76 |
Price Performance
Historical ComparisonAbout GDOT Green Dot Corporation $0.001 par value
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.